🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Crystalline cellulose simple occlusive dressing

    The First People's Hospital of Lianyungang

    Split-thickness Skin Graft Donor Sites

    phase 3 other completed

    1 trial

  2. Cyclophosphamide Injection 500 mg., Vincristine Sulfate 1 mg/ml solution for injection, Cisplatin 1 mg/ml concentrate for solution for infusion, Temodal 100 mg hard capsules, Etoposide 20 mg/ml Concentrate for Solution for Infusion, Thiotepa 15 mg Powder for solution for injection , Qarziba 4.5 mg/mL concentrate for solution for infusion, Melphalan 50 mg concentrate and solvent for solution for injection/infusion, Busulfan 6 mg/ml concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution

    The George Institute

    Patients with High Risk Neuroblastoma

    phase 3 small molecule active

    1 trial

  3. Cytarabine

    Hoffmann-La Roche

    Leukemia, Myeloid, Acute

    phase 3 small molecule terminated

    1 trial

  4. Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  5. Cytarabine

    The First People's Hospital of Lianyungang

    Leukemia

    phase 3 small molecule active

    1 trial

  6. Cytokine-Induced Killer Cells

    Sun Yat-sen University

    Carcinoma, Hepatocellular

    phase 3 mab completed

    1 trial

  7. DAPAGLIFLOZIN, Placebo for dapagliflozin film-coated tablets 10 mg

    Disc Medicine

    Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population

    phase 3 small molecule active

    1 trial

  8. DARATUMUMAB, LENALIDOMIDE, DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE, Etentamig, DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  9. DASATINIB, IMATINIB, BOSUTINIB, DASATINIB, NILOTINIB, BOSUTINIB, DASATINIB, DASATINIB, NILOTINIB, DASATINIB, IMATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  10. DAUNORUBICIN HYDROCHLORIDE, FLUDARABINE, MYLOTARG 5 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, TREOSULFAN, CYTARABINE, BUSULFAN

    Fondazione Telethon ETS

    Favorable-intermediate-risk Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  11. DBV712

    DBV Technologies

    Allergy, Peanut

    phase 3 small molecule active

    1 trial

  12. DCCR

    SOLENO THERAPEUTICS INC

    Prader-Willi Syndrome

    phase 3 small molecule active

    4 trials

  13. DEGARELIX, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, DEGARELIX, DEGARELIX, TRIPTORELIN , DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN

    Ningbo Cancer Hospital

    very high risk localized or locally advanced prostate cancer

    phase 3 small molecule active

    1 trial

  14. DEXAMETHASONE , DARATUMUMAB, DARZALEX 1800 mg solution for injection, LENALIDOMIDE

    Pari Pharma GmbH

    Onco-hematology

    phase 3 small molecule active

    1 trial

  15. DEXAMETHASONE , FLUDARABINE , CISPLATIN , OXALIPLATIN , CARBOPLATIN , LENALIDOMIDE , RITUXIMAB , TOCILIZUMAB , CYCLOPHOSPHAMIDE , BENDAMUSTINE , TISAGENLECLEUCEL, IFOSFAMIDE , MELPHALAN , CYTARABINE , CARMUSTINE , IBRUTINIB , ETOPOSIDE , GEMCITABINE

    Novartis Pharmaceuticals

    Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

    phase 3 small molecule active

    1 trial

  16. DEXAMETHASONE , MK-2870, -, -, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

    Merck Sharp and Dohme

    Metastatic non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  17. DEXAMETHASONE, DEXAMETHASONE, DEXAMETHASONE

    Pari Pharma GmbH

    Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is one of the most frequent primary neoplasms of the bone marrow

    phase 3 small molecule active

    1 trial

  18. DEXAMETHASONE, Dexamethasonfosfaat Accord 4 mg/ml oplossing voor injectie/infusie, Kyprolis 10 mg powder for solution for infusion, Paracetamol 1000mg Tablets, Imnovid 2 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, LYNOZYFIC 200 mg concentrate for solution for infusion, Dermodrin 30 mg/2 ml soluție injectabilă, Imnovid 3 mg hard capsules, DEXAMETHASONE, Co-Trimoxazole 80/400mg Tablets, Kyprolis 30 mg powder for solution for infusion, LYNOZYFIC 5 mg concentrate for s

    Lacuna Pharma Pty Ltd

    Relapsed Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  19. DEXAMETHASONE, POMALIDOMIDE, ELOTUZUMAB, CARFILZOMIB, BORTEZOMIB, DIPHENHYDRAMINE, DEXAMETHASONE, POMALIDOMIDE, DIPHENHYDRAMINE, Etentamig, PARACETAMOL, POMALIDOMIDE, BORTEZOMIB, SELINEXOR, PARACETAMOL, POMALIDOMIDE

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  20. DEXAMETHASONE, RITUXIMAB, BLINATUMOMAB, MERCAPTOPURINE, RITUXIMAB, BLINATUMOMAB, CYCLOPHOSPHAMIDE, PREDNISONE, CYTARABINE, IDARUBICIN, PREDNISOLONE, METHOTREXATE SODIUM, DEXAMETHASONE, DEXAMETHASONE, CYCLOPHOSPHAMIDE, PEGASPARGASE, DOXORUBICIN, CYTARABINE, DEXAMETHASONE, MERCAPTOPURINE, VINCRISTINE SULFATE, METHOTREXATE SODIUM, METHOTREXATE SODIUM, VINCRISTINE SULFATE, ASPARAGINASE, CRISANTASPASE, METHOTREXATE SODIUM

    Amgen

    Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia in older adults

    phase 3 small molecule active

    1 trial

  21. DEXAMETHASONE, Xtandi - 40 mg soft capsules, PF-06821497, DEXAMETHASONE, PF-06821497, PREDNISOLONE, DOCETAXEL

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  22. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 small molecule active

    1 trial

  23. DIAMICRON 60MG, comprimé sécable à libération modifiée, Placebo S05762, METFORMIN, Forxiga 10 mg film-coated tablets

    The George Institute

    Type 2 Diabetes inadequately controlled with dapagliflozin with or without metformin

    phase 3 small molecule active

    1 trial

  24. DIFLUPREDNATE, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe, 4D-150, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe

    4D Molecular Therapeutics

    Macular neovascularization secondary to age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources